Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Taysha Gene Therapies to Participate in Upcoming Gene Therapy Summit By: Taysha Gene Therapies, Inc. via Business Wire October 21, 2021 at 07:00 AM EDT Jefferies Gene Therapy & Editing Summit on October 28 at 11:00 am ET Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in a fireside chat at the Jefferies Gene Therapy & Editing Summit. Conference Details: Event: Jefferies Gene Therapy & Editing Summit Date: Thursday, October 28, 2021 Time: 11:00 am ET Format: Fireside Chat Participants: RA Session II, President, Founder and Chief Executive Officer Dr. Suyash Prasad, Chief Medical Officer and Head of R&D Kamran Alam, Chief Financial Officer Dr. Kimberly Lee, SVP, Corporate Communications and Investor Relations About Taysha Gene Therapies Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20211021005262/en/Contacts Company Contact: Kimberly Lee, D.O. SVP, Corporate Communications and Investor Relations Taysha Gene Therapies klee@tayshagtx.com Media Contact: Carolyn Hawley Canale Communications carolyn.hawley@canalecomm.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Taysha Gene Therapies to Participate in Upcoming Gene Therapy Summit By: Taysha Gene Therapies, Inc. via Business Wire October 21, 2021 at 07:00 AM EDT Jefferies Gene Therapy & Editing Summit on October 28 at 11:00 am ET Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in a fireside chat at the Jefferies Gene Therapy & Editing Summit. Conference Details: Event: Jefferies Gene Therapy & Editing Summit Date: Thursday, October 28, 2021 Time: 11:00 am ET Format: Fireside Chat Participants: RA Session II, President, Founder and Chief Executive Officer Dr. Suyash Prasad, Chief Medical Officer and Head of R&D Kamran Alam, Chief Financial Officer Dr. Kimberly Lee, SVP, Corporate Communications and Investor Relations About Taysha Gene Therapies Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20211021005262/en/Contacts Company Contact: Kimberly Lee, D.O. SVP, Corporate Communications and Investor Relations Taysha Gene Therapies klee@tayshagtx.com Media Contact: Carolyn Hawley Canale Communications carolyn.hawley@canalecomm.com
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in a fireside chat at the Jefferies Gene Therapy & Editing Summit. Conference Details: Event: Jefferies Gene Therapy & Editing Summit Date: Thursday, October 28, 2021 Time: 11:00 am ET Format: Fireside Chat Participants: RA Session II, President, Founder and Chief Executive Officer Dr. Suyash Prasad, Chief Medical Officer and Head of R&D Kamran Alam, Chief Financial Officer Dr. Kimberly Lee, SVP, Corporate Communications and Investor Relations About Taysha Gene Therapies Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20211021005262/en/
Company Contact: Kimberly Lee, D.O. SVP, Corporate Communications and Investor Relations Taysha Gene Therapies klee@tayshagtx.com Media Contact: Carolyn Hawley Canale Communications carolyn.hawley@canalecomm.com